Evidence map›Paper›PMID 19048200›Full record

ReviewHandbook of experimental pharmacology2009

Other inhibitors of viral enzymes and functions.

H Zimmermann, G Hewlett, H Rübsamen-Waigmann

Abstract readReview
In one paragraph

Review in Handbook of experimental pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

H ZimmermannAicuris GmbH und Co. KG, Bayer Pharma- und Chemiepark, Friedrich-Ebert-Str. 475, 42117 Wuppertal, Germany. holger.zimmermann@aicuris.com
G Hewlett
H Rübsamen-Waigmann

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Until the end of the 1970s, the mainstays of antiviral chemotherapy were nucleoside analogues that targeted virus polymerase, in particular, the herpesvirus DNA polymerase. The scourge of HIV triggered an unprecedented commitment to identify novel antivirals, and these efforts transformed antiviral therapy into the modern, sophisticated treatment form described in this book, with targets such as the reverse transcriptase and the protease as well as the entry of the human immunodeficiency virus. As the regulation of human pathogenic virus growth cycles became more understandable, the realisation grew that these pathogens had more than one Achilles heel that might be suitable targets for small molecules with antiviral activity. This chapter addresses those "other" targets as well as other approaches to the tried and tested polymerase inhibitors, the so-called non-nucleoside inhibitors of reverse transcriptase.

Indexed as

AnimalsAntiviral AgentsDnaB HelicasesEndodeoxyribonucleasesEnzyme InhibitorsHIV Integrase InhibitorsHIV Reverse TranscriptaseHumansReverse Transcriptase InhibitorsVirus AssemblyVirusesAntiviral AgentsDnaB HelicasesEndodeoxyribonucleasesEnzyme InhibitorsHIV Integrase InhibitorsHIV Reverse TranscriptaseReverse Transcriptase Inhibitorsterminase

Identifiers

PMID19048200
PMCPMC7122372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.